You may know Tom the fraudbuster but what about the man who makes you money from value investing shares tips - act TODAY!
New Bulletin Board Moron of the Week contest - sponsored by Paul "Queenie" McManus PR to London's worst frauds & AIM trash
The June edition of the UK Investor Magazine is live - 5 share Tips, voting guide, and where to emigrate if the wrong party wins
Published 32 days ago
Alliance Pharma (APH) has made an AGM update announcement, including that trading “is good and in line with the board's expectations” and that “cash flow in the business remains strong”. This is a healthy reaffirmation of our BUY tip of last month which is now well in the money.
Published 70 days ago
Specialty pharmaceutical company, Alliance Pharma (APH) is a previous successful share tip for us - recommended at 31p, with gains banked at 43p in 2015. However, there has since been positive development which looks inadequately reflected in a current sub 50p offer price and, noting also the continued presence of famed investors Nigel Wray and Slater Investments as major shareholders…
Published 75 days ago
In this video from the storming success that was the 2017 UK Investor Show, John Dawson, CEO of Alliance Pharma (APH), is at the podium. And make sure that you keep April 21 2018 free for next year's UK Investor Show.
Published 107 days ago
Time really is running out if you want to attend what is the country's biggest and most exciting one day event for those who are serious about making money from shares. UK Investor Show will be having a 15th birthday party on April 1 (no kidding) in Westminster, London. But as of today fewer than 400 of the 3,000 tickets are unallocated. So if you want to attend book one NOW!
Published 406 days ago
Alliance Pharma (APH) has, relatively, recently completed a transformational acquisition. I know that Nigel Wray remains a big fan as does Mark Slater. Sensible value investors should thus find the presentation by John Dawson of interest
Published 481 days ago
Hello Share Trekkies. The health game is a good place to be for winning share seekers like us in 2016. Bio-science firms are set to reap the benefit of an ageing world population with all its attendant health problems. And even younger folk will sadly require more medical care, unless they can do something about their unhealthy diets.
Published 581 days ago
Oh no Paul Scott is giving me health advice again. If he promises never ever to waterboard me again with online retail gross margins I might just quit smoking. Away from that I look at car crash Slater & Gordon (SGH) following up from the earlier detailed piece HERE. In a similar vein I look at NAHL (NAH). Then it is onto EKF Diagnostics (EKF), Moneyswap (SWAP), Oilex (OEX), Forte Energy (FTE), Alliance Pharma (APH), Iofina (IOF) and the Fitbug (FITB) dog. There is no mention of Jabba The Hutt today, David Lenigas must wait for Gold & Bears on Saturday for his next drubbing. And boy will it be a drubbing.
Published 620 days ago
Investment Case: As noted last month with Berkeley Energy, it is not a surprise to see eye-watering share price declines over previous years for stocks with sector: “Mining”. Shares in *Petropavlovsk plc, formerly Peter Hambro Mining, (POG) have particularly suffered – they down from more than 400p at the commencement of 2011 and more than 100p at the commencement of 2013 to a current 6.47p offer price – amidst a combination of sector-wide and company-specific challenges, the latter including a vast debt pile. However, a recent refinancing and refocusing – with production now being optimised from a cash generation point of view – now offer the promise of a decent recovery from current levels and the shares are a buy…the target price to sell is 19p within three years.
Published 760 days ago
Alliance Pharma (APH) has updated investors that “trading in the first four months of 2015 has been satisfactory” and that“we look forward to the remainder of 2015 with confidence.”
Published 782 days ago
Amiong those presenting in the healthcare and biotech master class were John Dawson of Alliance Pharma, Steve Moore, Adam Reynolds of Premaitha and Optibiotix, Venn Life and Collagen. Enjoy
Published 800 days ago
Alliance Pharma (APH) is a stock that Britain’s Buffett had held for ten years and it is also a great sleep-sound core portfolio buy for me. Its CEO John Dawson is a good man and I like the company. Anyhow he, and the CEOs of Rex Bionics, Accesso and Akers Biosciences, of which I know sweet FA are presenting in London at the Proactive forum this Thursday 23rd). There’s free food & booze on offer as well. And
Published 825 days ago
Speciality pharmaceuticals company Alliance Pharma (APH) has announced results for the 2014 calendar year and that “we enter 2015 well placed for resumed growth”. That is not discounted in the current share price.
Published 891 days ago
Speciality pharmaceutical company, Alliance Pharma (APH) has updated that 2014 “pre-tax profits are expected to be in line with current market expectations” on turnover of £43.5 million and that “we continue to evaluate a number of acquisition opportunities”.
Published 1019 days ago
Alliance Pharma (APH) last week announced results for the first half of the 2014 calendar year and that “we expect full year results to be in line with market expectations”. This makes the shares a buy at up to 35p
Published 1132 days ago
Alliance Pharma (APH) has updated investors attending its AGM that “trading in the first four months of 2014 has been in line with expectations” and that “we continue to work towards delivering further earnings enhancing acquisitions to outperform those plans”.
Published 1497 days ago
AIM-listed speciality pharmaceutical company Alliance Pharma (APH) has updated that “trading in the first four months of 2013 has been 6% ahead of the same period last year (5% on an underlying basis), with turnover of £15.1 million”.
Published 1531 days ago
A new stock, of which star fund manager Mark Slater is a fan, has just been added to the Growth Portfolio on the 'Nifty Fifty' website which I write with Tom Winnifrith.
Published 1539 days ago
Alliance Pharma (APH), the speciality pharmaceutical company which acquires and licenses established products in niche areas, announced its calendar 2012 results a couple of weeks ago. The numbers contained no nasty shocks. That is no surprise, one of the great attractions of Alliance is that there is a real visibility of revenues. I tipped the shares on my premium Nifty Fifty service at 31p (offer price) in December and they now trade at 36-37p but are still a buy.